Skip to main content

Table 1 Patient characteristics at baseline in the overall population (Prescribed Patient Set)

From: Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY® study

Study medication and characteristic

Empa

N = 1966

DPP4i

N = 1144

GLP-1 RA

N = 361

Other SGLT2i

N = 584

Total

N = 4055

(A) Demographics and clinical parameters relevant to T2D

 Age (years), mean (SD)

62.4 (9.5)

66.4 (10.8)

58.3 (10.8)

62.2 (9.2)

63.1 (10.2)

 Female (%)

45.8

55.9

47.6

48.3

49.1

 BMI (kg/m2), mean (SD)

33.2 (5.7)

31.1 (5.3)

36.3 (6.5)

33.4 (5.6)

32.9 (5.8)

 Non-black (%)a

99.3

99.4

99.4

99.1

99.3

 Years since T2D diagnosis, mean (SD)

9.9 (7.0)

9.8 (7.0)

9.8 (6.7)

10.0 (6.7)

9.9 (6.9)

 HbA1c (%), mean (SD)

8.3 (1.4)

8.0 (1.3)

8.4 (1.2)

8.6 (1.5)

8.3 (1.4)

 HbA1c ≥ 8.5% (%)

32.6

23.2

34.3

36.5

30.7

  Missing HbA1c (%)

9.9

6.6

5.0

8.0

8.3

(B) Clinical parameters relevant to CVD

 Systolic BP (mmHg), mean (SD)

137.3 (15.5)

136.7 (15.5)

136.6 (14.2)

136.7 (14.6)

137.0 (15.3)

 Diastolic BP (mmHg), mean (SD)

81.8 (9.0)

80.8 (9.0)

81.3 (9.5)

82.3 (8.8)

81.6 (9.0)

  Missing (%)

5.5

4.0

7.5

8.2

5.7

 LVEF (%), mean (SD)

57.6 (10.2)

59.0 (9.7)

59.5 (9.0)

58.1 (8.1)

58.1 (9.9)

 LVEF confirmed by echocardiography (%)

23.3

15.6

14.1

9.6

18.3

  Missing (%)

76.1

84.2

85.3

89.6

81.2

  Unknown (%)

0.5

0.3

0.3

0.3

0.4

 Total cholesterol (mml/L), mean (SD)

5.0 (1.2)

5.0 (1.2)

4.9 (1.2)

5.1 (1.3)

5.0 (1.2)

  Missing (%)

29.1

27.1

30.7

35.3

29.6

 LDL (mml/L), mean (SD)

2.7 (1.0)

2.8 (1.1)

2.6 (1.0)

2.7 (1.0)

2.7 (1.0)

  Missing (%)

44.8

44.1

41.0

51.0

45.1

 HDL (mml/L), mean (SD)

1.2 (0.4)

1.2 (0.3)

1.2 (0.3)

1.2 (0.3)

1.2 (0.4)

  Missing (%)

46.5

45.5

41.6

51.7

46.5

 Triglycerides (mml/L), mean (SD)

1.9 (0.8)

1.9 (0.7)

2.2 (1.7)

2.0 (1.0)

2.0 (0.9)

  Missing (%)

38.6

38.8

36.3

45.9

39.5

(C) Clinical parameters relevant to CKD

 Serum creatinine (mmol/L), mean (SD)

82.9 (21.4)

92.6 (33.0)

79.3 (19.2)

78.8 (16.8)

84.8 (25.1)

 eGFR (ml/min), mean (SD)

78.2 (18.4)

69.5 (22.6)

84.1 (19.1)

81.3 (17.2)

76.7 (20.1)

  Missing (%)

20.7

21.7

26.9

25.7

22.2

 UACR (mg/g), mean (SD)

84.6 (123.6)

100.9 (241.9)

45.0 (94.2)

89.7 (134.3)

86.2 (107.4)

 UACR (mg/g), median (Q1, Q3)

20.0 (4.6, 125.0)

12.7 (2.0, 123.0)

4.4 (0.9, 28.0)

23.5 (6.2, 96.0)

15.0 (2.7, 109.1)

  Missing (%)

80.4

76.0

74.8

83.2

79.1

  1. BP blood pressure, BMI body mass index, CKD chronic kidney disease, CVD cardiovascular disease, DPP4i dipeptidyl peptidase-4 inhibitor, eGFR estimated glomerular filtration rate, Empa empagliflozin, GLP-1 RA glucagon-like peptide-1 receptor agonist, HbA1c glycated haemoglobin, HDL high density lipoproteins, LDL low density lipoproteins, LVEF left ventricular ejection fraction, Q quartile, SD standard deviation, SGLT2i sodium-glucose cotransporter-2 inhibitor, T2D type 2 diabetes, UACR urine albumin-creatinine ratio.
  2. aAssessment of ethnicity (black or non-black) was necessary for calculation of eGFR (shown in Table 1c).